| Species |
Human |
| Protein Construction |
TNFSF12/TWEAK (Ser43-His249)_x000D_
Accession # O43508-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized TNFSF12/TWEAK hFc Chimera, Human at 5μg/ml (100μl/well) on the plate can bind Biotinylated AntiTNFSF12 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
49.62 kDa |
| Apparent Molecular Weight |
Due to enzyme lysis and glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS, 200mM L-arginine (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a well known multifunctional cytokine extensively distributed in cell types and tissues. Accumulating evidence has shown that TWEAK binding to the receptor factor-inducible 14 (Fn14) participates in diverse pathologic processes including cell proliferation and death, angiogenesis, carcinogenesis and inflammation. |
| Synonyms |
APO3 ligand; APO3L; DR3LG; UNQ181/PRO207; TWEAK; MGC129581 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
